Personalized vaccine therapy combined with immune checkpoint inhibitors for aggressive breast cancer
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
This study is testing a new personalized vaccine treatment for triple negative breast cancer that uses pieces from your own tumor to help boost your immune system and fight the cancer better.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Metaclipse Therapeutics Corporation NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10489848 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for triple negative breast cancer (TNBC), which is known for its aggressive nature and limited effective therapies. The study focuses on developing a personalized vaccine immunotherapy that uses tumor membrane vesicles derived from a patient's own tumor tissue, combined with immune checkpoint inhibitors. By targeting the unique antigens present in each patient's tumor, this approach aims to enhance the immune response against cancer cells. Patients will receive this novel therapy to potentially improve their treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer or those who have already responded well to existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with triple negative breast cancer, potentially improving survival rates.
How similar studies have performed: While the approach of personalized vaccine therapy is innovative, similar strategies have shown promise in other cancer types, indicating potential for success in this area.
Where this research is happening
Atlanta, United States
- Metaclipse Therapeutics Corporation — Atlanta, United States (Active)
Researchers
- Principal investigator: Pack, Christopher D — Metaclipse Therapeutics Corporation
- Study coordinator: Pack, Christopher D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.